Question follow-through · 32904
Mefloquine: Side Effects
To ask the Secretary of State for Health and Social Care, what guidance his Department gives to medical practitioners on the (a) risks of harmful long-term effects resulting from the prescription of Lariam (Mefloquine) as an anti-malarial prophylaxis and
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 24 Feb 2025
- Target answer date
- 27 Feb 2025
- Answer
- 27 Feb 2025 · 3 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Fenfluramine · 25 Feb 2025
- Surgical Mesh Implants · 26 Feb 2025
- Surgical Mesh Implants: Compensation · 26 Feb 2025
- Surgical Mesh Implants · 26 Feb 2025
- Palliative Care: Children · 31 Mar 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
24 Feb 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what guidance his Department gives to medical practitioners on the (a) risks of harmful long-term effects resulting from the prescription of Lariam (Mefloquine) as an anti-malarial prophylaxis and
27 Feb 2025
Target answer date
Date supplied by the official written-questions record.
27 Feb 2025
Answer published
Mefloquine, commercially known as Lariam, is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The current product information for mefloqui...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Fenfluramine
25 Feb 2025 · To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on the use of Fenfluramine to treat Lennox Gastaut Syndrome; and what representations his Department has had f
Surgical Mesh Implants
26 Feb 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to commission (a) research into, and (b) training programmes for, improved techniques for removal of failed pelvic mesh implants from injured women including those removal met
Surgical Mesh Implants: Compensation
26 Feb 2025 · To ask the Secretary of State for Health and Social Care, how many legal cases brought against the NHS by mesh-damaged women have been settled (a) in and (b) out of court in each of the past ten years.
Surgical Mesh Implants
26 Feb 2025 · To ask the Secretary of State for Health and Social Care, if he will publish current waiting lists totals at each of the mesh removal centres set up following the publication of the Cumberlege report; and whether mesh-damaged women are given an option to
Palliative Care: Children
31 Mar 2025 · To ask the Secretary of State for Health and Social Care, what (a) mechanisms exist and (b) steps he is taking to ensure that integrated care boards are accountable for their commissioning of children’s palliative care.
Paediatric Acute-onset Neuropsychiatric Syndrome and Paediatric Autoimmune Neuropsychiatric Disorders
30 Apr 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to facilitate the circulation of material to General Practitioners advising how to (a) recognise and (b) treat with (i) antibiotics and (ii) anti-inflammatory medications the
Breast Cancer
20 Jun 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to (a) increase awareness of, (b) improve screening for and (c) develop research into lobular breast cancer; and what recent discussions his Department has had with NHS Englan
Advanced Therapy Medicinal Products
20 Jun 2025 · To ask the Secretary of State for Health and Social Care, if he will designate a Minister in his Department to (a) have responsibility for the field of cell and gene therapies and (b) chair his Department's Advanced Therapies Medicinal Products Coordinati
Prostate Cancer: Screening
8 Sept 2025 · To ask the Secretary of State for Health and Social Care, what his policy is on (a) routine PSA testing for males in specific age categories and (b) the reimbursement of GP practices by the NHS for providing PSA tests; and whether he has made an assessmen
Prostate Cancer: Screening
8 Sept 2025 · To ask the Secretary of State for Health and Social Care, how many and what proportion of PSA tests have (a) accurately diagnosed, and (b) given false (i) negative and (ii) positive diagnoses for prostate cancer in the most recent year for which figures a
Prostate Cancer: Medical Treatments
27 Oct 2025 · To ask the Secretary of State for Health and Social Care, with reference to the National Cancer Audit Collaborating Centre's report entitled National Prostate Cancer Audit State of the Nation Report 2025, published in October 2025, what assessment his Dep
Psilocybin: Clinical Trials
28 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether he has received evidence on the potential clinical use of psilocybin under controlled conditions to treat serious psychiatric illness; whether his Department has made an assessment of the p